Annual report

Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥1.13T2025-04-01 → 2026-03-31Cons.Revenue IFRS
Revenue¥1.04T2024-04-01 → 2025-03-31Cons.Revenue IFRS
Revenue¥921.9bn2023-04-01 → 2024-03-31vCons.Revenue IFRS (5-year summary)
Revenue¥820.2bn2022-04-01 → 2023-03-31vCons.Revenue IFRS (5-year summary)
Revenue¥703.3bn2021-04-01 → 2022-03-31vCons.Revenue IFRS (5-year summary)
Operating income¥176.3bn2025-04-01 → 2026-03-31Cons.Operating profit loss IFRS
Operating income¥157.7bn2024-04-01 → 2025-03-31Cons.Operating profit loss IFRS
Profit before tax¥178.3bn2025-04-01 → 2026-03-31Cons.Profit loss before tax IFRS
Profit before tax¥154.6bn2024-04-01 → 2025-03-31Cons.Profit loss before tax IFRS
Profit before tax¥140.8bn2023-04-01 → 2024-03-31vCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥116.1bn2022-04-01 → 2023-03-31vCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥114.5bn2021-04-01 → 2022-03-31vCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥135.9bn2025-04-01 → 2026-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥117.0bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥106.4bn2023-04-01 → 2024-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥135.9bn2025-04-01 → 2026-03-31Cons.Profit loss IFRS
Net income¥117.0bn2024-04-01 → 2025-03-31Cons.Profit loss IFRS
Total assets¥2.31Tat 2026-03-31Cons.Assets IFRS
Total assets¥1.83Tat 2025-03-31Cons.Assets IFRS
Total assets¥1.83Tat 2024-03-31vCons.Total assets IFRS (5-year summary)
Total assets¥1.60Tat 2023-03-31vCons.Total assets IFRS (5-year summary)
Total assets¥1.47Tat 2022-03-31vCons.Total assets IFRS (5-year summary)
Total liabilities¥727.7bnat 2026-03-31Cons.Liabilities IFRS
Total liabilities¥459.9bnat 2025-03-31Cons.Liabilities IFRS
Net assets / equity¥1.58Tat 2026-03-31Cons.Equity IFRS
Net assets / equity¥1.37Tat 2025-03-31Cons.Equity IFRS
Net assets / equity¥1.33Tat 2024-03-31vCons.Equity IFRS
Equity (owners)¥1.58Tat 2026-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.37Tat 2025-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.33Tat 2024-03-31vCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥1.11Tat 2023-03-31vCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥1.01Tat 2022-03-31vCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥280.5bnat 2026-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥221.9bnat 2025-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥204.9bnat 2024-03-31vCons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31vCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥205.3bnat 2022-03-31vCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥230.9bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥210.8bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥146.3bn2023-04-01 → 2024-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥344.1bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥82.5bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥81.5bn2023-04-01 → 2024-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow¥155.5bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥108.8bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥62.1bn2023-04-01 → 2024-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥92.142025-04-01 → 2026-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥79.012024-04-01 → 2025-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥71.52023-04-01 → 2024-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥59.52022-04-01 → 2023-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥58.722021-04-01 → 2022-03-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥92.122025-04-01 → 2026-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥78.992024-04-01 → 2025-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥71.472023-04-01 → 2024-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥59.482022-04-01 → 2023-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥58.692021-04-01 → 2022-03-31vCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥1,074.18at 2026-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥927.85at 2025-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥893.8at 2024-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥746.07at 2023-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥669.23at 2022-03-31vCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio68.5%at 2026-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.8%at 2025-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio72.5%at 2024-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE9.2%2025-04-01 → 2026-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE8.7%2024-04-01 → 2025-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE8.7%2023-04-01 → 2024-03-31vCons.Rate of return on equity IFRS (5-year summary)
ROE8.4%2022-04-01 → 2023-03-31vCons.Rate of return on equity IFRS (5-year summary)
ROE9.5%2021-04-01 → 2022-03-31vCons.Rate of return on equity IFRS (5-year summary)
Employees31,185at 2026-03-31Cons.Number of employees
Employees30,689at 2025-03-31Cons.Number of employees
Employees30,591at 2024-03-31vCons.Number of employees
Employees30,207at 2023-03-31vCons.Number of employees
Employees28,294at 2022-03-31vCons.Number of employees
Revenue¥452.2bn2025-04-01 → 2026-03-31StandaloneNet sales
Revenue¥428.7bn2024-04-01 → 2025-03-31StandaloneNet sales
Revenue¥399.8bn2023-04-01 → 2024-03-31vStandaloneNet sales (5-year summary)
Revenue¥375.0bn2022-04-01 → 2023-03-31vStandaloneNet sales (5-year summary)
Revenue¥341.4bn2021-04-01 → 2022-03-31vStandaloneNet sales (5-year summary)
Operating income¥100.9bn2025-04-01 → 2026-03-31StandaloneOperating income
Operating income¥89.4bn2024-04-01 → 2025-03-31StandaloneOperating income
Ordinary income¥174.5bn2025-04-01 → 2026-03-31StandaloneOrdinary income
Ordinary income¥147.8bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥110.7bn2023-04-01 → 2024-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥91.1bn2022-04-01 → 2023-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥79.4bn2021-04-01 → 2022-03-31vStandaloneOrdinary income loss (5-year summary)
Profit before tax¥198.1bn2025-04-01 → 2026-03-31StandaloneIncome before income taxes
Profit before tax¥148.3bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Net income¥158.9bn2025-04-01 → 2026-03-31StandaloneProfit loss
Net income¥122.3bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥87.9bn2023-04-01 → 2024-03-31vStandaloneNet income loss (5-year summary)
Net income¥79.0bn2022-04-01 → 2023-03-31vStandaloneNet income loss (5-year summary)
Net income¥62.8bn2021-04-01 → 2022-03-31vStandaloneNet income loss (5-year summary)
Total assets¥1.58Tat 2026-03-31StandaloneAssets
Total assets¥1.42Tat 2025-03-31StandaloneAssets
Total assets¥1.44Tat 2024-03-31vStandaloneTotal assets (5-year summary)
Total assets¥1.33Tat 2023-03-31vStandaloneTotal assets (5-year summary)
Total assets¥1.28Tat 2022-03-31vStandaloneTotal assets (5-year summary)
Total liabilities¥597.1bnat 2026-03-31StandaloneLiabilities
Total liabilities¥549.7bnat 2025-03-31StandaloneLiabilities
Net assets / equity¥987.5bnat 2026-03-31StandaloneNet assets
Net assets / equity¥870.0bnat 2025-03-31StandaloneNet assets
Net assets / equity¥813.8bnat 2024-03-31vStandaloneNet assets
Net assets / equity¥765.6bnat 2023-03-31vStandaloneNet assets (5-year summary)
Net assets / equity¥765.4bnat 2022-03-31vStandaloneNet assets (5-year summary)
Cash and deposits¥88.5bnat 2026-03-31StandaloneCash and deposits
Cash and deposits¥69.8bnat 2025-03-31StandaloneCash and deposits
EPS (basic)¥107.752025-04-01 → 2026-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥82.582024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥59.052023-04-01 → 2024-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥52.612022-04-01 → 2023-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥41.522021-04-01 → 2022-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥107.722025-04-01 → 2026-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥82.562024-04-01 → 2025-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥59.032023-04-01 → 2024-03-31vStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥52.592022-04-01 → 2023-03-31vStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥41.492021-04-01 → 2022-03-31vStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥302025-04-01 → 2026-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥262024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥442023-04-01 → 2024-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥402022-04-01 → 2023-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥342021-04-01 → 2022-03-31vStandaloneDividend paid per share (5-year summary)
Net assets per share¥669.07at 2026-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥589.54at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥547.68at 2024-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥513.67at 2023-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥505.54at 2022-03-31vStandaloneNet assets per share (5-year summary)
Equity ratio62.3%at 2026-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio61.2%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio56.6%at 2024-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio57.4%at 2023-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-03-31vStandaloneEquity to asset ratio (5-year summary)
ROE17.1%2025-04-01 → 2026-03-31StandaloneRate of return on equity (5-year summary)
ROE14.5%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE11.1%2023-04-01 → 2024-03-31vStandaloneRate of return on equity (5-year summary)
ROE10.3%2022-04-01 → 2023-03-31vStandaloneRate of return on equity (5-year summary)
ROE8.4%2021-04-01 → 2022-03-31vStandaloneRate of return on equity (5-year summary)
Shares issued1,480,559,000at 2026-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued1,480,559,000at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued745,348,000at 2024-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued747,682,000at 2023-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2022-03-31vStandaloneTotal number of issued shares (5-year summary)
Employees5,736at 2026-03-31StandaloneNumber of employees
Employees5,633at 2025-03-31StandaloneNumber of employees
Employees5,554at 2024-03-31vStandaloneNumber of employees
Employees5,457at 2023-03-31vStandaloneNumber of employees
Employees5,377at 2022-03-31vStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2025-04-01 → 2026-03-31¥924m
Reconciling Itemsreconcilingrevenue external2025-04-01 → 2026-03-31¥294m
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2026-03-31−¥1.5bn
Blood And Cell Technologies Companyreportable segmentcapex2025-04-01 → 2026-03-31¥21.7bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2026-03-316557 pure
Blood And Cell Technologies Companyreportable segmentrevenue external2025-04-01 → 2026-03-31¥231.0bn
Blood And Cell Technologies Companyreportable segmentsegment profit2025-04-01 → 2026-03-31¥33.6bn
Cardiac And Vascular Companyreportable segmentcapex2025-04-01 → 2026-03-31¥36.7bn
Cardiac And Vascular Companyreportable segmentemployeesat 2026-03-3117007 pure
Cardiac And Vascular Companyreportable segmentrevenue external2025-04-01 → 2026-03-31¥676.4bn
Cardiac And Vascular Companyreportable segmentsegment profit2025-04-01 → 2026-03-31¥164.0bn
Medical Care Solutions Companyreportable segmentcapex2025-04-01 → 2026-03-31¥36.7bn
Medical Care Solutions Companyreportable segmentemployeesat 2026-03-316331 pure
Medical Care Solutions Companyreportable segmentrevenue external2025-04-01 → 2026-03-31¥216.1bn
Medical Care Solutions Companyreportable segmentsegment profit2025-04-01 → 2026-03-31¥21.6bn
Terumo Organ Technologiesreportable segmentcapex2025-04-01 → 2026-03-31¥1.1bn
Terumo Organ Technologiesreportable segmentemployeesat 2026-03-31238 pure
Terumo Organ Technologiesreportable segmentrevenue external2025-04-01 → 2026-03-31¥8.0bn
Terumo Organ Technologiesreportable segmentsegment profit2025-04-01 → 2026-03-31¥1.7bn
—segment totalcapex2025-04-01 → 2026-03-31¥96.2bn
—segment totalrevenue external2025-04-01 → 2026-03-31¥1.13T
—segment totalsegment profit2025-04-01 → 2026-03-31¥220.9bn
Reconciling Itemsreconcilingcapex2024-04-01 → 2025-03-31¥2.6bn
Reconciling Itemsreconcilingrevenue external2024-04-01 → 2025-03-31¥298m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2025-03-31−¥712m
Blood And Cell Technologies Companyreportable segmentcapex2024-04-01 → 2025-03-31¥17.8bn
Blood And Cell Technologies Companyreportable segmentrevenue external2024-04-01 → 2025-03-31¥200.3bn
Blood And Cell Technologies Companyreportable segmentsegment profit2024-04-01 → 2025-03-31¥26.5bn
Cardiac And Vascular Companyreportable segmentcapex2024-04-01 → 2025-03-31¥43.6bn
Cardiac And Vascular Companyreportable segmentrevenue external2024-04-01 → 2025-03-31¥624.4bn
Cardiac And Vascular Companyreportable segmentsegment profit2024-04-01 → 2025-03-31¥154.7bn
Medical Care Solutions Companyreportable segmentcapex2024-04-01 → 2025-03-31¥18.5bn
Medical Care Solutions Companyreportable segmentrevenue external2024-04-01 → 2025-03-31¥211.2bn
Medical Care Solutions Companyreportable segmentsegment profit2024-04-01 → 2025-03-31¥23.0bn
—segment totalcapex2024-04-01 → 2025-03-31¥79.8bn
—segment totalrevenue external2024-04-01 → 2025-03-31¥1.04T
—segment totalsegment profit2024-04-01 → 2025-03-31¥204.2bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2026-03-31287 pure
Cardiac And Vascular Companyreportable segmentemployeesat 2026-03-312128 pure
Medical Care Solutions Companyreportable segmentemployeesat 2026-03-312469 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,844
ItemContextValueUnit
Retained earnings IFRSCurrentYearInstant1116479000000JPY
Other components of equity IFRSPrior1YearInstant276800000000JPY
Other components of equity IFRSCurrentYearInstant392110000000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant1368535000000JPY
Equity attributable to owners of parent IFRSCurrentYearInstant1584509000000JPY
Equity IFRSPrior1YearInstant1368535000000JPY
Equity IFRSCurrentYearInstant1584509000000JPY
Liabilities and equity IFRSPrior1YearInstant1828393000000JPY
Liabilities and equity IFRSCurrentYearInstant2312234000000JPY
Revenue IFRSPrior1YearDuration1036171000000JPY
Revenue IFRSCurrentYearDuration1131877000000JPY
Cost of sales IFRSPrior1YearDuration475501000000JPY
Cost of sales IFRSCurrentYearDuration537201000000JPY
Gross profit IFRSPrior1YearDuration560670000000JPY
Gross profit IFRSCurrentYearDuration594675000000JPY
Selling general and administrative expenses IFRSPrior1YearDuration381648000000JPY
Selling general and administrative expenses IFRSCurrentYearDuration409937000000JPY
Other income IFRSPrior1YearDuration6592000000JPY
Other income IFRSCurrentYearDuration9184000000JPY
Other expenses IFRSPrior1YearDuration27944000000JPY
Other expenses IFRSCurrentYearDuration17601000000JPY
Operating profit loss IFRSPrior1YearDuration157668000000JPY
Operating profit loss IFRSCurrentYearDuration176320000000JPY
Finance income IFRSPrior1YearDuration3624000000JPY
Finance income IFRSCurrentYearDuration6248000000JPY
Finance costs IFRSPrior1YearDuration6247000000JPY
Finance costs IFRSCurrentYearDuration3286000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YearDuration-470000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYearDuration-1029000000JPY
Profit loss before tax IFRSPrior1YearDuration154574000000JPY
Profit loss before tax IFRSCurrentYearDuration178252000000JPY
Income tax expense IFRSPrior1YearDuration37595000000JPY
Income tax expense IFRSCurrentYearDuration42337000000JPY
Profit loss IFRSPrior1YearDuration116978000000JPY
Profit loss IFRSCurrentYearDuration135914000000JPY
Profit loss attributable to owners of parent IFRSPrior1YearDuration116978000000JPY
Profit loss attributable to owners of parent IFRSCurrentYearDuration135914000000JPY
Profit loss IFRSPrior1YearDuration116978000000JPY
Profit loss IFRSCurrentYearDuration135914000000JPY
Basic earnings loss per share IFRSPrior1YearDuration79.01
Basic earnings loss per share IFRSCurrentYearDuration92.14
Diluted earnings loss per share IFRSPrior1YearDuration78.99
Diluted earnings loss per share IFRSCurrentYearDuration92.12
Profit loss IFRSPrior1YearDuration116978000000JPY
Profit loss IFRSCurrentYearDuration135914000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YearDuration589000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYearDuration8282000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YearDuration4861000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYearDuration-1223000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YearDuration5451000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2025-03-31pass rounding
balance sheet identityconsolidated 2026-03-31pass
balance sheet identitynon_consolidated 2025-03-31pass
balance sheet identitynon_consolidated 2026-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2026-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2026-03-31pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenueconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenueconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2025-04-01/2026-03-31pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2026-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2026-03-31pass